{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T10:15:23Z","timestamp":1763460923316,"version":"3.45.0"},"reference-count":45,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: High-dose cisplatin (\u2265200 mg\/m2 cumulative) remains the standard of care in concurrent chemoradiotherapy (CRT) for locally advanced head and neck squamous cell carcinoma (LA-HNSCC). However, its use is frequently limited by nephrotoxicity, including acute kidney disease (AKD). This recently described clinical renal syndrome encompasses functional alterations of the kidney lasting fewer than 3 months post-exposure. Although hydration protocols and antiemetic strategies are routinely applied to avoid reduction in oral liquid intake and to prevent dehydration that could worsen renal function, AKD continues to pose a threat to reach the therapeutic dose, to treatment completion, and long-term outcomes. Recent evidence supports the nephroprotective role of intravenous (IV) magnesium in mitigating cisplatin-induced tubular injury, yet prospective data on its impact in real-world LA-HNSCC settings remain limited. We aimed to prospectively investigate the incidence and characteristics of renal impairment, particularly AKD, in a real-world cohort of LA-HNSCC patients treated with high-dose cisplatin and standardized supportive therapy, including intravenous magnesium. Methods: We conducted a prospective observational study including 207 patients with LA- HNSCC undergoing high-dose cisplatin-based CRT (\u2265200 mg\/m2 cumulative dose), within a standardized supportive care protocol incorporating IV magnesium. Renal function was assessed over three cycles via serum creatinine and estimated glomerular filtration rate (eGFR). AKD was defined and staged according to KDIGO criteria. Clinical and biochemical predictors of AKD were explored. Results: AKD occurred in 5.3% of patients (11\/207; 95% CI 2.7\u20139.3), with eight events between C1\u2192C2, 3 between C2\u2192C3, and 0 thereafter; recovery at the next cycle was 9.1% (1\/11). Among them, 57.1% were classified as stage 1. A baseline eGFR &lt; 90 mL\/min\/1.73 m2 was associated with a higher AKD incidence (13.3% vs. 5.4%). Body mass index (BMI) was significantly associated with AKD in univariate analysis (p = 0.02), whereas no independent predictor emerged in multivariate analysis. Use of renin\u2013angiotensin\u2013aldosterone system (RAAS) inhibitors was more frequent among patients who developed AKD (p = 0.04). Renal function declined more steeply in AKD patients, with a median eGFR slope of \u22120.3917 mL\/min\/1.73 m2\/day vs. \u22120.0483 mL\/min\/1.73 m2\/day in those without AKD (p = 0.0005), irrespective of CKD stage. Conclusions: In a real-world cohort receiving high-dose cisplatin with structured nephroprotection including IV magnesium, AKD developed in approximately 10% of patients. Lower baseline eGFR, elevated BMI, and RAAS inhibitor use emerged as potential risk factors. These findings reinforce the importance of proactive renal monitoring and suggest a role for magnesium supplementation as an accessible strategy to enhance renal safety in curative-intent CRT.<\/jats:p>","DOI":"10.3390\/cancers17203310","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T10:37:14Z","timestamp":1760438234000},"page":"3310","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Emerging Role of Magnesium in Preventing Acute Kidney Disease During Concurrent Chemoradiotherapy in Head and Neck Cancer"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4205-8959","authenticated-orcid":false,"given":"Francesco","family":"Trevisani","sequence":"first","affiliation":[{"name":"Department of Urology, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy"},{"name":"Urological Research Institute URI, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8311-5409","authenticated-orcid":false,"given":"Andrea","family":"Angioi","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Dialysis, and Transplantation, ARNAS G. Brotzu, 09047 Cagliari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Floris","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Dialysis, and Transplantation, ARNAS G. Brotzu, 09047 Cagliari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8006-6197","authenticated-orcid":false,"given":"Sara","family":"Cardellini","sequence":"additional","affiliation":[{"name":"Clinical Nutrition, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9094-4205","authenticated-orcid":false,"given":"Leone","family":"Giordano","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberta","family":"Culiersi","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnese","family":"Monti","sequence":"additional","affiliation":[{"name":"Urological Research Institute URI, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1475-0940","authenticated-orcid":false,"given":"Aurora","family":"Mirabile","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa031317","article-title":"Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer","volume":"349","author":"Forastiere","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","article-title":"Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients","volume":"92","author":"Pignon","year":"2009","journal-title":"Radiother. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.2003.01.008","article-title":"An Intergroup Phase III Comparison of Standard Radiation Therapy and Two Schedules of Concurrent Chemoradiotherapy in Patients with Unresectable Squamous Cell Head and Neck Cancer","volume":"21","author":"Adelstein","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13046-020-01715-7","article-title":"Oral mucositis: The hidden side of cancer therapy","volume":"39","author":"Pulito","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/ohn.302","article-title":"Expert Consensus Statement: Management of Dysphagia in Head and Neck Cancer Patients","volume":"168","author":"Kuhn","year":"2023","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"ref_6","first-page":"c179","article-title":"KDIGO Clinical Practice Guidelines for Acute Kidney Injury","volume":"120","author":"Khwaja","year":"2012","journal-title":"Kidney Int. Suppl."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nrneph.2017.2","article-title":"Acute Kidney Disease and Renal Recovery: Consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup","volume":"13","author":"Chawla","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/MAJ.0b013e31812dfe1e","article-title":"Cisplatin nephrotoxicity: A review","volume":"334","author":"Yao","year":"2007","journal-title":"Am. J. Med. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.3390\/toxins2112490","article-title":"Mechanisms of Cisplatin Nephrotoxicity","volume":"2","author":"Miller","year":"2010","journal-title":"Toxins"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/sj.ki.4496104","article-title":"Antiretroviral drugs and the kidney: Further precisions","volume":"68","author":"Izzedine","year":"2005","journal-title":"Kidney Int."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1200\/JCO.2017.74.9457","article-title":"Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial","volume":"36","author":"Noronha","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_12","first-page":"13","article-title":"Nephrotoxicity in locally advanced head and neck cancer: When the end justifies the means to preserve nutritional status during chemoradiation","volume":"33","author":"Cardellini","year":"2024","journal-title":"Support. Care Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0305-7372(89)90002-9","article-title":"Non-chemotherapeutic agents that potentiate chemotherapy efficacy","volume":"16","author":"Stewart","year":"1989","journal-title":"Cancer Treat. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1200\/JCO.2007.14.8841","article-title":"Factors Associated with Severe Late Toxicity After Concurrent Chemoradiation for Locally Advanced Head and Neck Cancer: An RTOG Analysis","volume":"26","author":"Machtay","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1053\/ctrv.1999.0097","article-title":"Cisplatin and hypomagnesemia","volume":"25","author":"Lajer","year":"1999","journal-title":"Cancer Treat. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1200\/JCO.2002.08.171","article-title":"Phase II Trial of The Pegylated Liposomal Doxorubicin in Previously Treated Metastatic Endometrial Cancer: A Gynecologic Oncology Group study","volume":"20","author":"Muggia","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.toxlet.2015.06.012","article-title":"An integrated view of cisplatin-induced nephrotoxicity and ototoxicity","volume":"237","author":"Karasawa","year":"2015","journal-title":"Toxicol. Lett."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1172\/JCI200215606","article-title":"TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity","volume":"110","author":"Ramesh","year":"2002","journal-title":"J. Clin. Investig."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1001\/jamaoncol.2025.0756","article-title":"Intravenous Magnesium and Cisplatin-Associated Acute Kidney Injury","volume":"11","author":"Gupta","year":"2025","journal-title":"JAMA Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Zaurito, P., Calado, A., Quarta, L., Longoni, M., Scilipoti, P., Santangelo, A., Viti, A., Cosenza, A., Scuderi, S., and Barletta, F. (2025). Incidence and Predictors of Acute Kidney Injury and Acute Kidney Disease After Robot-Assisted Radical Prostatectomy in Prostate Cancer Patients. Eur. Urol. Oncol.","DOI":"10.1016\/j.euo.2025.06.011"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.kint.2021.06.028","article-title":"Harmonizing Acute and Chronic Kidney Disease Definition and Classification: Report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference","volume":"100","author":"Lameire","year":"2021","journal-title":"Kidney Int."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Trevisani, F., Di Marco, F., Quattrini, G., Lepori, N., Floris, M., Valsecchi, D., Giordano, L., Dell\u2019oCa, I., Cardellini, S., and Cinque, A. (2023). Acute kidney injury and acute kidney disease in high-dose cisplatin-treated head and neck cancer. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1173578"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/NT.0000000000000092","article-title":"Body Mass Index","volume":"50","author":"Nuttall","year":"2015","journal-title":"Nutr. Today"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C","volume":"367","author":"Inker","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1159\/000504649","article-title":"Renal Function Assessment Gap in Clinical Practice: An Awkward Truth","volume":"45","author":"Trevisani","year":"2020","journal-title":"Kidney Blood Press. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"154","DOI":"10.34067\/KID.0005622020","article-title":"Hypomagnesemia in the Cancer Patient","volume":"2","author":"Workeneh","year":"2021","journal-title":"Kidney360"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3892\/mco.2020.2127","article-title":"Risk factors for cisplatin-induced acute kidney injury: A pilot study on the usefulness of genetic variants for predicting nephrotoxicity in clinical practice","volume":"13","author":"Oda","year":"2020","journal-title":"Mol. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Galfetti, E., Cerutti, A., Ghielmini, M., Zucca, E., and Wannesson, L. (2020). Risk factors for renal toxicity after inpatient cisplatin administration. BMC Pharmacol. Toxicol., 21.","DOI":"10.1186\/s40360-020-0398-3"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Lyrio, R.M.d.C., Rocha, B.R.A., Corr\u00eaa, A.L.R.M., Mascarenhas, M.G.S., Santos, F.L., Maia, R.d.H., Segundo, L.B., de Almeida, P.A.A., Moreira, C.M.O., and Sassi, R.H. (2024). Chemotherapy-induced acute kidney injury: Epidemiology, pathophysiology, and therapeutic approaches. Front. Nephrol., 4.","DOI":"10.3389\/fneph.2024.1436896"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1634\/theoncologist.2017-0015","article-title":"Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data","volume":"22","author":"Szturz","year":"2017","journal-title":"Oncologist"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/jnci\/djy133","article-title":"Cisplatin Every 3 Weeks Versus Weekly with Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck","volume":"111","author":"Bauml","year":"2018","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10157-023-02386-2","article-title":"A systematic review for prevention of cisplatin-induced nephrotoxicity using different hydration protocols and meta-analysis for magnesium hydrate supplementation","volume":"28","author":"Li","year":"2023","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Volarevic, V., Djokovic, B., Jankovic, M.G., Harrell, C.R., Fellabaum, C., Djonov, V., and Arsenijevic, N. (2019). Molecular mechanisms of cisplatin-induced nephrotoxicity: A balance on the knife edge between renoprotection and tumor toxicity. J. Biomed. Sci., 26.","DOI":"10.1186\/s12929-019-0518-9"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"F369","DOI":"10.1152\/ajprenal.00127.2014","article-title":"Magnesium protects against cisplatin-induced acute kidney injury by regulating platinum accumulation","volume":"307","author":"Solanki","year":"2014","journal-title":"Am. J. Physiol. Physiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1634\/theoncologist.2016-0319","article-title":"A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity","volume":"22","author":"Crona","year":"2017","journal-title":"Oncologist"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"100351","DOI":"10.1016\/j.esmoop.2021.100351","article-title":"Preloading magnesium attenuates cisplatin-associated nephrotoxicity: Pilot randomized controlled trial (PRAGMATIC study)","volume":"7","author":"Suppadungsuk","year":"2021","journal-title":"ESMO Open"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1007\/s10147-024-02629-6","article-title":"Relationship between magnesium dosage and the preventive effect on cisplatin-induced nephrotoxicity: Meta-analysis and meta-regression analysis","volume":"29","author":"Okamoto","year":"2024","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/jnci\/djy167","article-title":"Acute Kidney Injury in Patients Receiving Systemic Treatment for Cancer: A Population-Based Cohort Study","volume":"111","author":"Kitchlu","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.7150\/jca.45382","article-title":"Acute Kidney Injury in Oncology Patients","volume":"11","author":"Wang","year":"2020","journal-title":"J. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1080\/14656566.2024.2346268","article-title":"Pharmacotherapy considerations in patients who develop acute kidney injury during anti-cancer therapy","volume":"25","author":"Parodi","year":"2024","journal-title":"Expert Opi. Pharmacother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"821","DOI":"10.34067\/KID.0000000000000448","article-title":"Tubular Injury Biomarkers to Predict CKD and Hypertension at 3 Months Post-Cisplatin in Children","volume":"5","author":"Huang","year":"2024","journal-title":"Kidney360"},{"key":"ref_43","unstructured":"Chebotareva, N., Zhukova, L., Krasnova, T., and Grechukhina, K. (2023). NGAL\/KIM-1 as Early Cisplatin Nephrotoxicity Biomarkers (ASCO Abstract), ASCO Publications."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1093\/oncolo\/oyad297","article-title":"Hydration Methods for Cisplatin Containing Chemotherapy: A Systematic Review","volume":"29","author":"Sikking","year":"2023","journal-title":"Oncologist"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e2100275","DOI":"10.1200\/GO.21.00275","article-title":"The Effect of Intravenous Mannitol Combined with Normal Saline in Preventing Cisplatin-Induced Nephrotoxicity: A Randomized, Double-Blind, Placebo-Controlled Trial","volume":"8","author":"Sainamthip","year":"2022","journal-title":"JCO Glob. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/20\/3310\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T10:09:45Z","timestamp":1763460585000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/20\/3310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":45,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["cancers17203310"],"URL":"https:\/\/doi.org\/10.3390\/cancers17203310","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2025,10,14]]}}}